[144] Twist Bioscience Corporation SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Twist Bioscience (TWST) reports a proposed sale of 2,265 common shares through Fidelity Brokerage Services with an aggregate market value of $58,346.17 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired on 09/05/2025 through restricted stock vesting from the issuer and payment was recorded as compensation. The filer has sold 10,455 common shares in the past three months across four transactions (06/20/2025: 1,678; 07/02/2025: 476; 08/04/2025: 5,585; 08/21/2025: 2,716) generating gross proceeds of $300,156.58. Outstanding shares listed are 60,360,925. The filer affirms no undisclosed material adverse information and the notice includes the statutory signature/representation language.

Positive

• Proper Rule 144 disclosure completed, including broker, acquisition details, and signature representation
• Recent sales and proposed sale fully itemized with dates and gross proceeds for transparency

Negative

• Insider sold 10,455 shares in the past three months, totaling $300,156.58 in gross proceeds, which may warrant investor attention
• Proposed sale follows recent sales, indicating continued insider liquidity needs (as disclosed)

Insights

Securities Analyst

TL;DR: Routine insider sale of vested restricted stock totaling modest value relative to outstanding shares; disclosed per Rule 144.

The filing documents a planned sale of 2,265 shares valued at $58,346.17 that were acquired via restricted stock vesting on 09/05/2025 and marked as compensation. The filer previously sold 10,455 shares in the prior three months for $300,156.58. Given the issuer's 60,360,925 shares outstanding, these transactions are small in absolute share count and appear to be standard insider liquidity events rather than material corporate developments.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure observed; representation of no undisclosed material information included.

The notice follows Rule 144 disclosure requirements: it identifies acquisition method as restricted stock vesting, specifies broker, sale timing, and recent insider sales, and contains the required representation about material information. From a governance perspective, the filing demonstrates compliance and transparency on insider sales, with no company governance actions or irregularities disclosed in this document.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2265	58346.17	60360925	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Restricted Stock Vesting	Issuer			2265	09/05/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	06/20/2025	1678	59996.39
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	07/02/2025	476	17227.92
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	5585	158413.50
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2025	2716	70518.77

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Twist Bioscience (TWST) report?

The form reports a proposed sale of 2,265 common shares valued at $58,346.17 through Fidelity with an approximate sale date of 09/08/2025.

How were the 2,265 shares acquired according to the filing?

The shares were acquired on 09/05/2025 via restricted stock vesting from the issuer and payment is recorded as compensation.

How many shares did the filer sell in the past three months and for how much?

The filer sold 10,455 shares on four dates (06/20/2025, 07/02/2025, 08/04/2025, 08/21/2025) generating total gross proceeds of $300,156.58.

Who is the broker and where will the shares be sold?

The broker is listed as Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI) and the sale is to occur on NASDAQ.

What representation does the filer make about material information?

By signing the form, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.